Nurix Therapeutics, Inc. (NRIX)
15.95
-9.87
(-38.23%)
USD |
NASDAQ |
Nov 04, 16:00
15.97
+0.02
(+0.13%)
After-Hours: 07:29
Nurix Therapeutics Price to Book Value : 1.799 for Nov. 4, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 04, 2026 | 1.799 |
| November 03, 2026 | 2.912 |
| November 02, 2026 | 2.898 |
| October 30, 2026 | 3.022 |
| October 29, 2026 | 3.058 |
| October 28, 2026 | 3.074 |
| October 27, 2026 | 3.011 |
| October 26, 2026 | 2.881 |
| October 23, 2026 | 2.858 |
| October 22, 2026 | 2.877 |
| October 21, 2026 | 2.934 |
| October 20, 2026 | 2.943 |
| October 19, 2026 | 2.812 |
| October 16, 2026 | 2.754 |
| October 15, 2026 | 2.814 |
| October 14, 2026 | 2.669 |
| October 13, 2026 | 2.496 |
| October 12, 2026 | 2.499 |
| October 09, 2026 | 2.520 |
| October 08, 2026 | 2.505 |
| October 07, 2026 | 2.563 |
| October 06, 2026 | 2.549 |
| October 05, 2026 | 2.580 |
| October 02, 2026 | 2.593 |
| October 01, 2026 | 2.632 |
| Date | Value |
|---|---|
| September 30, 2026 | 2.674 |
| September 29, 2026 | 2.670 |
| September 28, 2026 | 2.669 |
| September 25, 2026 | 2.595 |
| September 24, 2026 | 2.667 |
| September 23, 2026 | 2.693 |
| September 22, 2026 | 2.895 |
| September 21, 2026 | 2.866 |
| September 18, 2026 | 2.869 |
| September 17, 2026 | 2.876 |
| September 16, 2026 | 2.836 |
| September 15, 2026 | 2.800 |
| September 14, 2026 | 2.878 |
| September 11, 2026 | 2.831 |
| September 10, 2026 | 2.911 |
| September 09, 2026 | 2.961 |
| September 08, 2026 | 2.947 |
| September 04, 2026 | 2.948 |
| September 03, 2026 | 2.855 |
| September 02, 2026 | 2.912 |
| September 01, 2026 | 2.937 |
| August 31, 2026 | 2.907 |
| August 28, 2026 | 6.751 |
| August 27, 2026 | 6.922 |
| August 26, 2026 | 6.880 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Gilead Sciences, Inc. | 16.61 |
| ACADIA Pharmaceuticals, Inc. | 2.828 |
| Alnylam Pharmaceuticals, Inc. | 5.984 |
| Anika Therapeutics, Inc. | 1.989 |
| Savara, Inc. | 6.663 |
Price to Book Value Related Metrics
| PE Ratio | 6.896 |
| PS Ratio | 2.456 |
| Price to Free Cash Flow | 4.662 |
| Price | 15.95 |
| Earnings Yield | 14.50% |
| Market Cap | 1.742B |
| Operating PE Ratio | 5.952 |
| Normalized PE Ratio | 6.896 |